Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

European, Observational, Prospective Study to Evaluate the Benefit/Risk of Vandetanib in RET Mutation Negative and Positive Patients With Symptomatic, Aggressive, Sporadic, Unresectable, Locally Advanced/Metastatic Medullary Thyroid Cancer

Next Previous
Trial Profile

European, Observational, Prospective Study to Evaluate the Benefit/Risk of Vandetanib in RET Mutation Negative and Positive Patients With Symptomatic, Aggressive, Sporadic, Unresectable, Locally Advanced/Metastatic Medullary Thyroid Cancer

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 13 Jul 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vandetanib (Primary)
  • Indications Thyroid cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Caprelsa104
  • Sponsors Sanofi Genzyme

    • Most Recent Events

    • 09 Feb 2016 Planned End Date changed from 1 Oct 2016 to 1 Sep 2019 as reported by ClinicalTrials.gov.
    • 09 Feb 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Sep 2019 as reported by ClinicalTrials.gov.
    • 09 Dec 2015 Planned End Date changed from 1 Oct 2018 to 1 Oct 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top